LEADER 01445nam  2200421 a 450 
001 9910692509603321
005 20040713154826.0
035   $a(CKB)5470000002354363
035   $a(OCoLC)55899688
035 9 $aocm55899688
035   $a(OCoLC)995470000002354363
035   $a(EXLCZ)995470000002354363
100   $a20040713d2000      ua             0
101 0 $aeng
135   $auran||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aPrescription drugs$b[electronic resource] $emany factors affected FDA's approval of selected "pipeline" drugs : report to congressional requesters
210  1$a[Washington, D.C.] :$cU.S. General Accounting Office,$d[2000]
300   $aTitle from title screen (viewed on July 6, 2004).
300   $a"August 2000."
300   $aPaper version available from: U.S. General Accounting Office, 441 G St., NW, Rm. LM, Washington, D.C. 20548.
300   $a"GAO/HEHS-00-140."
320   $aIncludes bibliographical references.
517   $aPrescription drugs 
606   $aPatent medicines$zUnited States
606   $aPatent extensions$zUnited States
606   $aDrugs$zUnited States$xTesting
615  0$aPatent medicines
615  0$aPatent extensions
615  0$aDrugs$xTesting.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910692509603321
996   $aPrescription drugs$92884258
997   $aUNINA